Original title: Treatment of Femoropopliteal In-Stent Restenosis With Paclitaxel-Eluting Stents. Zilver PTX Global Registry. ZILVER-PTX. Reference: Thomas Zeller et al. J Am Coll Cardiol Intv 2013;6:274–81. Femoropopliteal in-stent restenosis (ISR) is reported in between 19% and 37% of lesions a year and this incidence increases with lesion length. The ZILVER-PTX study tested the self-expanding paclitaxel-eluting nitinol stent (Cook<a href="https://solaci.org/en/2013/04/08/n-2829/" title="Read more" >...</a>
Rotational atherectomy is only an interim strategy.
Original title: High-Speed Rotational Atherectomy Before Paclitaxel-Eluting Stent Implantation in Complex Calcified Coronary Lesions. The Randomized ROTAXUS (Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease) Trial. Reference: Mohamed Abdel-Wahab et al. J Am Coll Cardiol Intv 2013; article in press Heavily calcified lesions are difficult and may prevent the appropriate expansion of a<a href="https://solaci.org/en/2013/01/04/n-3137/" title="Read more" >...</a>
Future strategies to prevent restenosis and stent thrombosis
Original title: Endothelial cell repopulation after stenting determines in-stent neointima formation: effects of bare-metal vs. drug-eluting stents and genetic endothelial cell modification. Reference: Douglas G et al. European Heart Journal doi:10.1093/eurheartj/ehs240 Experimental models of vascular injury have shown that the rate of endothelial cell repopulation post-injury is a critical factor in determining subsequent neointima formation as well as<a href="https://solaci.org/en/2012/12/04/n-3277/" title="Read more" >...</a>
Cilostazol reduces restenosis in infrapopliteal angioplasty
Original title: Impact of Cilostazol on Angiographic Restenosis after Balloon Angioplasty for Infrapopliteal Artery Disease in Patients with Critical Limb Ischemia Reference: Y. Soga et al. European Journal of Vascular and Endovascular Surgery 44 (2012) 577e581. Angioplasty is regularly used for patients with critical limb ischemia where restenosis is a great limitation, especially in infrapopliteal territory. The use<a href="https://solaci.org/en/2012/11/30/n-3837/" title="Read more" >...</a>
A new paradigm in the treatment of in-stent restenosis?
Original title: ISAR DESIRE 3: Drug-eluting balloon is best option for restenosis of limus-eluting stents Reference: Dr Robert Byrne. TCT 2012. Miami, Fl. The first of the ISAR DESIRE trials showed that drug-eluting stents (DES) were the best strategy for treating restenosis of a bare metal stent, the second ISAR DESIRE trial tested the hypothesis of changing or<a href="https://solaci.org/en/2012/11/11/n-3746/" title="Read more" >...</a>
Drug eluting balloon; a valid alternative to treat in-stent restenosis in the superficial femoral artery
Original title: Drug-Eluting Balloon for Treatment of Superficial Femoral Artery In-Stent Restenosis Reference: Eugenio Stabile et al. Journal of the American College of Cardiology 60:1739–42 (2012) Drug eluting balloon; a valid alternative to treat in-stent restenosis in the superficial femoral artery This prospective registry included 39 patients who received Paclitaxel-Eluting Balloon Angioplasty, (IN.PACT, Medtronic, Minneapolis, Minnesota), for in-stent<a href="https://solaci.org/en/2012/11/09/n-3739/" title="Read more" >...</a>
Diabetics with multivessel, must keep waiting.
Original title: Strategies for Multivessel Revascularization in Patients with Diabetes. The FREEDOM Trial. Reference: Michael E. Farkouh et al. N Engl J Med 2012. DOI: 10.1056/NEJMoa1211585 This study was designed to determine the best revascularization strategy in diabetic patients with multivessel using current techniques of angioplasty (PCI) and surgery (CABG). Randomized 1:1 diabetic patients with injuries > 70%<a href="https://solaci.org/en/2012/11/08/n-3732/" title="Read more" >...</a>
Drug-Eluting Stents: device without polymers overcomes limitations of first generations stents
The NEXT randomized trial showed the superiority of a polymer-free amphilimus-eluting stent compared to paclitaxel-eluting stents with permanent polymers The NEXT clinical trial (International Randomized Comparison Between DES Limus Carbostent and Taxus Drug-Eluting Stents in the Treatment of De Novo Coronary Lesions), is a multicenter randomized trial (n=296) comparing coronary amphilimus eluting stent Cre8 (CID,<a href="https://solaci.org/en/2012/10/01/n-3935/" title="Read more" >...</a>